Pharma Mar, S.A. (PMRA.F)

32,02 +0,44 (+1,39%) Ab 08:08AM CEST. Markt geöffnet.

Pharma Mar, S.A.

Avenida de los Reyes, 1
Pol. Industrial La Mina – Norte Colmenar Viejo
Madrid 28770
Spain
34 91 846 60 00
https://www.pharmamar.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 509

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Jose Maria Fernandez Sousa-Faro Ph.D.	Founder, Executive Chairman, CEO & President	294k	N/A	N/A
Mr. Pedro Francisco Fernandez Puentes	Executive Vice-Chairman	124k	N/A	N/A
Mr. Juan Carlos-Torres Carretero	Founder	N/A	N/A	1949
Ms. María Luisa de Francia Caballero	Chief Financial Officer	N/A	N/A	N/A
Mr. José Luis Moreno Martinez-Losa	Head of Capital Markets & Investor Relations	N/A	N/A	N/A
Mr. Juan Gomez Pulido	General Counsel & Secretary of the Board of Directors	N/A	N/A	N/A
Ms. Sandra Llamera Sanchez	Global Compliance Head	N/A	N/A	N/A
Ms. Lara Vadillo	Communication Director	N/A	N/A	N/A
Ms. Belén Sopesén Veramendi Ph.D.	Director of Corporate Development	N/A	N/A	N/A
Mr. Luis Rupérez Cuenca	Director of Human Resources & IT	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2015 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.

Corporate Governance

Pharma Mar, S.A.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 8. Die grundlegenden Scores sind Audit: 3, Vorstand: 9, Shareholderrechte: 7, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.